Download MendeleyKynurenine-3-Monooxygenase Inhibition Prevents Multiple Organ Failure in Rodent Models of Acute Pancreatitis.
Mole, D.J., Webster, S.P., Uings, I., Zheng, X., Binnie, M., Wilson, K., Hutchinson, J.P., Mirguet, O., Walker, A., Beaufils, B., Ancellin, N., Trottet, L., Beneton, V., Mowat, C.G., Wilkinson, M., Rowland, P., Haslam, C., Mcbride, A., Homer, N.Z., Baily, J.E., Sharp, M.G., Garden, O.J., Hughes, J., Howie, S.E., Holmes, D.S., Liddle, J., Iredale, J.P.(2016) Nat Med 22: 202
- PubMed: 26752518
- DOI: https://doi.org/10.1038/nm.4020
- Primary Citation of Related Structures:
5FN0 - PubMed Abstract:
Acute pancreatitis (AP) is a common and devastating inflammatory condition of the pancreas that is considered to be a paradigm of sterile inflammation leading to systemic multiple organ dysfunction syndrome (MODS) and death. Acute mortality from AP-MODS exceeds 20% (ref. 3), and the lifespans of those who survive the initial episode are typically shorter than those of the general population. There are no specific therapies available to protect individuals from AP-MODS. Here we show that kynurenine-3-monooxygenase (KMO), a key enzyme of tryptophan metabolism, is central to the pathogenesis of AP-MODS. We created a mouse strain that is deficient for Kmo (encoding KMO) and that has a robust biochemical phenotype that protects against extrapancreatic tissue injury to the lung, kidney and liver in experimental AP-MODS. A medicinal chemistry strategy based on modifications of the kynurenine substrate led to the discovery of the oxazolidinone GSK180 as a potent and specific inhibitor of KMO. The binding mode of the inhibitor in the active site was confirmed by X-ray co-crystallography at 3.2 Å resolution. Treatment with GSK180 resulted in rapid changes in the levels of kynurenine pathway metabolites in vivo, and it afforded therapeutic protection against MODS in a rat model of AP. Our findings establish KMO inhibition as a novel therapeutic strategy in the treatment of AP-MODS, and they open up a new area for drug discovery in critical illness.
Organizational Affiliation:
Medical Research Council Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK.
